Study Summary
This trial is testing a new combo treatment for CLL/SLL to see how effective it is at getting rid of disease.
Eligible Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 1 year
1 year
establish the rate of minimum residual disease (MRD) undetectable response
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
1 Treatment Group
BOVEN regimen
1 of 1
Experimental Treatment
127 Total Participants · 1 Treatment Group
Primary Treatment: Venetoclax · No Placebo Group · Phase 2
BOVEN regimenExperimental Group · 3 Interventions: Obinutuzumab, Venetoclax, Zanubrutinib · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Obinutuzumab
FDA approved
Venetoclax
FDA approved
Zanubrutinib
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Who is running the clinical trial?
Roche-GenentechIndustry Sponsor
21 Previous Clinical Trials
2,517 Total Patients Enrolled
Massachusetts General HospitalOTHER
2,699 Previous Clinical Trials
30,843,035 Total Patients Enrolled
BeiGene USA, Inc.Industry Sponsor
2 Previous Clinical Trials
194 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,290 Total Patients Enrolled
Andrew Zelenetz, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
209 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:References
- Soumerai, Jacob D, Anthony R Mato, Ahmet Dogan, Venkatraman E Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, et al.. 2021. “Zanubrutinib, Obinutuzumab, and Venetoclax with Minimal Residual Disease-driven Discontinuation in Previously Untreated Patients with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: A Multicentre, Single-arm, Phase 2 Trial”. The Lancet Haematology. Elsevier BV. doi:10.1016/s2352-3026(21)00307-0.
- 2019. "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03824483.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments